Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection
 (with or without HIV coinfection) can be shortened when treating with the interferon-free
 therapy sofosbuvir/velpatasvir (SOF/VEL).

 SOF/VEL is a new treatment for hepatitis C called direct acting antiviral which targets the
 hepatitis C virus replication cycle and has been shown in phase II studies in chronic HCV to
 be highly effective (SVR12 >95%) when given for 12 weeks.

 Data has shown that treatment can be shortened when treating recently acquired HCV with
 interferon containing treatments. It is not known whether treatment with SOF/VEL can be
 shortened.

 This study aims to find out if treatment for 6 weeks with open-label SOF/VEL is equivalent to
 treatment for 12 weeks with SOF/VEL in participants with recently acquired hepatitis C
 infection. The project is a randomised study where both participants and investigators would
 not find out the treatment duration of the participants until week 6 of treatment.
Globally, 3-4 million new HCV infections are estimated to occur annually. People who inject
 drugs (PWID) represent one of the groups at highest risk of transmitting and acquiring
 infection with the majority of new (60%) and existing (80%) infections in developed countries
 occur in this population with HCV antibody prevalence estimated at 67% (60-80%). HIV-positive
 men-who-have-sex-with-men (MSM) are another high risk group for HCV acquisition.

 Direct acting antivirals (DAA) has changed the treatment landscape for individuals with
 chronic HCV infection with interferon-free therapy offering high effectiveness and
 tolerability, even in "difficult-to-treat" populations.

 Given the burden of HCV-related disease among PWID and HIV-positive MSM, strategies to
 enhance HCV assessment, treatment and prevention in these groups are urgently needed. Much of
 what is known about the timing of treatment initiation, regimen choice and duration of
 therapy in acute HCV infection comes from small observational studies and randomized
 controlled (randomly assigned into one or other of the different treatment groups)trials in
 selected populations with limited data on treatment in PWID and HIV co-infection. With recent
 rapid advances in HCV treatments, management strategies for acute HCV will evolve rapidly
 over the next few years.

 The REACT study will compare the efficacy and safety of open-label SOF/VEL administered for 6
 or 12 weeks in individuals with recent HCV infection. Participants will be randomised into
 receiving 6 weeks or 12 weeks treatment. Both investigators and participants will be blinded
 to the treatment duration until week 6 of treatment. The role and activity of DAA regimens in
 acute HCV infection requires evaluation, with the potential to be given as highly effective,
 short course interferon-sparing regimens, maximising acceptability to patients, encouraging
 uptake of treatment, limiting further transmission and preventing progression to chronic
 liver disease.
Inclusion Criteria:

 -  Subjects must meet all of the following inclusion criteria to be eligible to
 participate in this study:

 1. Participants have voluntarily signed the informed consent form.

 2. 18 years of age or older.

 3. Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the
 investigator is unlikely to demonstrate spontaneous viral clearance

 4. HCV genotypes 1-6.

 5. HBsAg negative

 6. Compensated liver disease (Child-Pugh A)

 7. Negative pregnancy test at baseline (females of childbearing potential only).

 8. Medically stable on the basis of physical examination, medical history and vital
 signs

 9. Adequate English to provide reliable responses to the study questionnaires

 10. All fertile males and females must be using effective contraception during
 treatment and during the 30 days after treatment end.

 11. Recently acquired HCV infection (estimated duration of infection ≤12 months)*

 Recently acquired HCV infection as defined by:

 A) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Documented
 anti-HCV Ab negative within the 12 months prior to anti-HCV antibody positive result

 OR

 B) i) First anti-HCV Ab or HCV RNA positive within the previous 3 months and ii) Acute
 clinical hepatitis [jaundice or alanine aminotransferase (ALT)] > 10 X ULN) within the
 previous 6 months prior to first positive HCV antibody or HCV RNA, with no other cause of
 acute hepatitis identifiable

 OR

 C) For cases of recent HCV reinfection the following criteria are required:

 Documented prior HCV antibody positive with HCV RNA negative on at least 2 occasions 6
 months apart AND new HCV RNA positive within the previous 6 months

 *Estimated duration of infection based on midpoint between last antibody negative or HCV
 RNA and first antibody positive or HCV RNA in the case of seroconversion and 6 weeks prior
 to date of maximum ALT in the case of acute hepatitis.

 If co-infection with HIV is documented, the subject must meet the following criteria:

 1. Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with cluster of
 differentiation 4 (CD4) T cell count >500 cells/mm3 OR

 2. On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count
 >200 cells/mm3 and an undetectable plasma HIV RNA level.

 -  Suitable ARV include:

 -  Tenofovir (TDF) and tenofovir alafenamide (TAF)

 -  Emtricitabine (FTC)

 -  Rilpivirine

 -  Dolutegravir

 -  Elvitegravir/cobicistat

 -  Contraindicated ARV include:

 -  Efavirenz 50% reduction in velpatasvir (GS-5816) exposure

 -  Didanosine

 -  Zidovudine

 -  Tipranavir Other ARV agents may be permissible at the time of study
 commencement pending further drug-drug interaction studies; please discuss
 with Study Principal Investigator.

 Exclusion criteria:

 Subjects who meet any of the exclusion criteria are not to be enrolled in this study.

 1. History of any of the following:

 1. Clinically significant illness (other than HCV) or any other major medical
 disorder that may interfere with the participant treatment, assessment or
 compliance with the protocol; participants currently under evaluation for a
 potentially clinically significant illness (other than HCV) are also excluded.

 2. History of chronic pulmonary disease associated with functional limitation,
 severe cardiac disease, major organ transplantation or other evidence of severe
 illness, malignancy, or any other conditions which would make the patient, in the
 opinion of the investigator, unsuitable for the study

 3. Solid organ transplant

 4. Malignancy within 5 years prior to screening, with exception of specific cancers
 that may have been cured by surgical resection (basal cell skin cancer, etc.).
 Subjects under evaluation for possible malignancy are also excluded.

 5. Significant drug allergy (such as anaphylaxis or hepatotoxicity).

 2. Subject shows evidence of significant liver disease in addition to hepatitis C, which
 may include but is not limited to drug- or alcohol-related cirrhosis, autoimmune
 hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis (NASH), or
 primary biliary cirrhosis

 3. Subject has known cirrhosis

 4. Any of the following lab parameters at screening:

 1. Direct bilirubin > 1.5 x ULN

 2. Platelets < 50,000/μL

 3. Creatinine clearance (CLcr) < 60 mL/min

 4. Haemoglobin < 11 g/dL for females ; < 12 g/dL for males

 5. Albumin < 30g/L

 5. Pregnant or nursing female.

 6. Use of prohibited concomitant medications as described in section 5.2 in the protocol

 7. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone
 equivalent > 10 mg/day)

 8. Known hypersensitivity to velpatasvir, sofosbuvir or formulation excipients.

 9. Therapy with any anti-neoplastic or immunomodulatory treatment (including
 supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of
 study drug.

 10. Any investigational drug ≤6 weeks prior to the first dose of study drug.

 11. Previous failure of therapy with sofosbuvir or an non-structural protein 5A (NS5A)
 inhibitor prior to the first dose of study drug.

 12. Ongoing severe psychiatric disease as judged by the treating physician.

 13. Frequent injecting drug use that is judged by the treating physician to compromise
 treatment safety.

 14. Inability or unwillingness to provide informed consent or abide by the requirements of
 the study.